FDA approves percutaneous transmural arterial bypass system for treatment of complex PAD
Endologix announced that the FDA has granted approval of its percutaneous transmural arterial bypass system for the treatment of complex peripheral arterial disease.
The system (Detour) is designed to enable physicians to bypass lesions in the superficial femoral artery using stents routed through the femoral vein to restore blood flow to the leg, according to a company press release.
Image: Adobe Stock
This approach is especially effective for lesions 20 cm to 46 cm in length, after failed endovascular procedures or for suboptimal candidates for open surgical bypass, according to the release.
“We are delighted to receive FDA approval of the Detour system,” Matt Thompson, MD, President and CEO of Endologix, said in the release. “[Percutaneous transmural arterial bypass] therapy represents a significant step forward for patients with complex PAD, they have long needed a more effective and less invasive treatment option for long lesions of the [superficial femoral artery]. We are proud to be pioneering this novel approach and continuing to innovate on behalf of patients. We look forward to launching this new therapy in the U.S. through a targeted market release in the coming weeks.”
Collapse